Author(s):
Ananya K V, Amit B Patil, D V Gowda, Preethi S
Email(s):
ananyakana@gmail.com
DOI:
10.5958/0974-360X.2020.00700.3 
Address:
Ananya K V, Amit B Patil, D V Gowda, Preethi S
Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysuru, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 8,
Year - 2020
ABSTRACT:
Throughout the world needle-free type of vaccination has become priority as it eradicates the chance of unsafe and wrong use of needles and it reduces complexity of the procedure. Many routes have been explored in the same. Mucosal route is most important among others. Mucosal routes include nasal, oral, sublingual, buccal, ocular, rectal, vaginal routes. For treating allergic hypersensitivities, sublingual mucosa has been targeted for many years. Nevertheless, sublingual vaccine delivery received little attention recently. Latest studies demonstrated the capability of sublingual vaccination to induce mucosal and systemic responses against many antigens. (Like soluble proteins, live attenuated viruses and inter particulate antigens) This review summarizes the latest discoveries that proves the sublingual vaccine delivery is potential to provide protection against several mucosal pathogens.
Cite this article:
Ananya K V, Amit B Patil, D V Gowda, Preethi S. Adjuvants employed in the Fabrication of sublingual vaccines. Research J. Pharm. and Tech. 2020; 13(8):3957-3962. doi: 10.5958/0974-360X.2020.00700.3
Cite(Electronic):
Ananya K V, Amit B Patil, D V Gowda, Preethi S. Adjuvants employed in the Fabrication of sublingual vaccines. Research J. Pharm. and Tech. 2020; 13(8):3957-3962. doi: 10.5958/0974-360X.2020.00700.3 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-8-73
REFERENCES:
1. Visweswaran V, Binoy A, Sreenivas A, Abhinand B, Vijayan M. Vaccines-Pillars of Preventive Health. Res J Pharm Technol. 2017;10(9):951–8.
2. Aher VD, Banerjee S, Mahaur KK. Vaccine: An ultimate way of immunization. Res J Pharm Technol. 2011;4(3):369–74.
3. Alam N, Agrawal OP, Rimpi, Alam P, Agrawal S, Kaushik M, et al. Natural immunoenhancers. Res J Pharm Technol. 2011;4(10):1526–32.
4. Behbehani a M. The smallpox story: life and death of an old disease. Microbiol Rev. 1983;47(4):455–509.
5. Johansson M, Schön K, Ward M, Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in gamma interferon receptor-deficient mice despite a strong local immunoglobulin a response. Infect Immun. 1997;65(3):1032–44.
6. Ermak TH, Giannasca PJ, Nichols R, Myers GA, Nedrud J, Weltzin R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med [Internet]. 1998;188(12):2277–88. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2212427andtool=pmcentrezandrendertype=abstract
7. Harandi AM, Svennerholm B, Holmgren J, Eriksson K. Interleukin-12 (IL-12) and IL-18 Are Important in Innate Defense against Genital Herpes Simplex Virus Type 2 Infection in Mice but Are Not Required for the Development of Acquired Gamma Interferon-Mediated Protective Immunity. J Virol. 2002;75(14):6705–9.
8. Faith VH, Debnath S, Lavanya D, Jerusha V, Madhuri MVR. Food as a Vaccine. Res J Pharm Dos Forms Technol. 2015;7(2):161.
9. Minor PD. Live attenuated vaccines: Historical successes and current challenges. Virology [Internet]. 2015;1–14. Available from: http://dx.doi.org/10.1016/j.virol.2015.03.032
10. Human W-, Cells D, Plotkin SA, Farquhar JD, Katz M, Buser F. Attenuation of RA 27 / 3 Rubella Virus. 2016;(Table 2).
11. Sabin AB. Studies on Variants of Poliomyelitis Virus: I. Experimental Segregation and Properties of Avirulent Variants of Three Immunologic Types. J Exp Med. 2004;99(6):551–76.
12. Maurice R Hilleman, Robert E Weibel, Eugene B. Buynak Joseph Stokes and James E Whitman. Live, attenuated mumps-virus vaccine. New J Med [Internet]. 1967;319(24):1557–62.
13. Holmgren J, Svennerholm AM, Jertborn M, Clemens J, Sack DA, Salenstedt R, et al. An oral B subunit: whole cell vaccine against cholera. Vaccine. 1992;10(13):911–4.
14. J. A. Doull, G. S. Shibley, Grace E. Haskin, Huldah Bancroft, J. E. McCLELLAND, Helena Hoelscher AM. active immunization against pertussis. 2015;58(October 1939).
15. hopkins. Atgabe. Diphtheria Toxoid as an Immunizing Agent. Can Med Assoc J. 1927;17(5):524–9.
16. Shabaka A, López V, Manzanara D, Zapata N, Ángeles MDL, De M, et al. S320 Transplantation. 2018;(July):2018.
17. Francis T. Vaccination With Influenza. 1935;604–6.
18. Narendrakumar G, Dey R, Godavarthi SS, Preethi T V. Effect of baculovirus with adjuvants against helicoverpa armigera (HBN) on cotton and evaluation of its effect in different instar. Res J Pharm Technol. 2017;10(7):2111–3.
19. Gadhave DU, Gaikwad PS, Pimpodkar N V., Udugade SB. DNA vaccines: A hope full ray in Immunology. Asian J Res Pharm Sci. 2015;5(2):126.
20. Health G, Strategy S, Ending T, Hepatitis V. Viral hepatitis 2016–2021. 2016;(June).
21. Jaurigue JA, Seeberger PH. Parasite Carbohydrate Vaccines. 2017;7(June):1–12.
22. History T. PASSAGE # 1 Different Types of Vaccines.
23. Record WE, States M, Group A. Conference report. 2010; 28:589–90.
24. Patil S, Maske A, Sapkale G, Kure A. Unique Approaches to Vaccine Development Formulation and Delivery. Res J Pharmacol Pharmacodyn. 2010;2(2):99–102.
25. Kalaivani M, Pulikottil MJ, Bm NM, Sakthivel R, Rajasekaran A. Preparation and Characterisation of Alginate Coated Chitosan Microspheres for Bacterial Vaccines. 2010;3(June):503–6.
26. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine. 2007;25(30 SPEC. ISS.):5467–84.
27. Nair PNR, Schroeder HE. Local immune response to repeated topical antigen application in the simian labial mucosa. Infect Immun. 1983;41(1):399–409.
28. Quiding M, Nordström I, Kilander A, Andersson G, Hanson LÅ, Holmgren J, et al. Intestinal immune responses in humans: Oral cholera vaccination induces strong intestinal antibody responses and interferon-γ production and evokes local immunological memory. J Clin Invest. 1991;88(1):143–8.
29. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun. 1997;65(4):1387–94.
30. Jertborn M, Nordström I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect Immun. 2001;69(6):4125–8.
31. Johansson EL, Wassén L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun. 2001;69(12):7481–6.
32. Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: A human vaccine delivery strategy using a patch. Nat Med. 2000;6(12):1403–6.
33. Brandtzaeg P, Pabst R. Let’s go mucosal: Communication on slippery ground. Trends Immunol. 2004;25(11):570–7.
34. Suzuki K, Fagarasan S. How host-bacterial interactions lead to IgA synthesis in the gut. Trends Immunol. 2008;29(11):523–31.
35. Lokhande SS. A Review on Intranasal Drug Delivery System with Recent Advancement. Res J Top Cosmet Sci. 2018;9(1):12.
36. Chinchore M V., Kothawade PD, Surwase RK, Maru AD. Formulation, optimization and evaluation of amlodipine besylate sublingual films. Res J Pharm Technol. 2014;7(8):840–4.
37. Cuburu N, Kweon M-N, Hervouet C, Cha H-R, Pang Y-YS, Holmgren J, et al. Sublingual Immunization with Nonreplicating Antigens Induces Antibody-Forming Cells and Cytotoxic T Cells in the Female Genital Tract Mucosa and Protects against Genital Papillomavirus Infection. J Immunol. 2009;183(12):7851–9.
38. Kim S, Joo DH, Lee JB, Shim BS, Cheon IS, Jang JE, et al. Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant. PLoS One. 2012;7(2).
39. Park HJ, Ferko B, Byun YH, Song JH, Han GY, Roethl E, et al. Sublingual immunization with a live attenuated influenza A virus lacking the nonstructural protein 1 induces broad protective immunity in mice. PLoS One. 2012;7(6).
40. Shim B-S, Choi Y, Cheon IS, Song MK. Sublingual Delivery of Vaccines for the Induction of Mucosal Immunity. Immune Netw. 2013;13(3):81.
41. Shim BS, Choi YK, Yun CH, Lee EG, Jeon YS, Park SM, et al. Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza. PLoS One. 2011;6(11):1–10.
42. Shim BS, Stadler K, Nguyen HH, Yun CH, Kim DW, Chang J, et al. Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J. 2012; 9:1–9.
43. Hervouet C, Luci C, Çuburu N, Cremel M, Bekri S, Vimeux L, et al. Sublingual immunization with an HIV subunit vaccine induces antibodies and cytotoxic T cells in the mouse female genital tract. Vaccine. 2010;28(34):5582–90.
44. Song J-H, Nguyen HH, Cuburu N, Horimoto T, Ko S-Y, Park S-H, et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci. 2008;105(5):1644–9.
45. Kildsgaard J, Brimnes J, Jacobi H, Lund K. Sublingual immunotherapy in sensitized mice. Ann Allergy, Asthma Immunol [Internet]. 2007;98(4):366–72. Available from: http://dx.doi.org/10.1016/S1081-1206(10)60884-8
46. Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy. 2007;37(4):488–97.
47. Noonan PK, Benet LZ. Incomplete and delayed bioavailability of sublingual nitroglycerin. Am J Cardiol. 1985;55(1):184–7.
48. Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P, et al. Safety of various dosage regimens during induction of sublingual immunotherapy: A preliminary study. Int Arch Allergy Immunol. 2002;129(3):248–53.
49. Olaguíbel JM, Álvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Investig Allergol Clin Immunol. 2005;15(1):9–16.
50. Agostinis F, Tellarini L, Canonica GW, Falagiani P, Passalacqua G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy Eur J Allergy Clin Immunol. 2005;60(1):133.
51. Viswanathan RK, Busse WW. Allergen immunotherapy in allergic respiratory diseases: From mechanisms to meta-analyses. Chest. 2012;141(5):1303–14.
52. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond. J Allergy Clin Immunol. 2011;127(1):30–8.
53. Larsen TH, Poulsen LK, Melac M, Combebias A, Andre C, Malling HJ. Safety and tolerability of grass pollen tablets in sublingual immunotherapy - A phase-1 study. Allergy Eur J Allergy Clin Immunol. 2006;61(10):1173–6.
54. Huo Z, Bissett SL, Giemza R, Beddows S, Oeser C, Lewis DJM. Systemic and mucosal immune responses to sublingual or intramuscular Human Papilloma Virus antigens in healthy female volunteers. PLoS One. 2012;7(3):1–8.
55. Kim SH, Kim JY, Choi Y, Nguyen HH, Song MK, Chang J. Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection. PLoS One. 2013;8(9):1–11.
56. Kim JY, Choi Y, Nguyen HH, Song MK, Chang J. Mucosal Immunization with Recombinant Adenovirus Encoding Soluble Globular Head of Hemagglutinin Protects Mice Against Lethal Influenza Virus Infection. Immune Netw. 2013;13(6):275.
57. Fu YH, Jiao YY, He JS, Giang GY, Zhang W, Yan YF, et al. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. Antiviral Res [Internet]. 2014;105(1):72–9. Available from: http://dx.doi.org/10.1016/j.antiviral.2014.02.003
58. Domm W, Brooks L, Chung HL, Feng C, Bowers WJ, Watson G, et al. Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: Association with mucoadhesion and efficient penetration of the sublingual barrier. Vaccine [Internet]. 2011;29(40):7080–9. Available from: http://dx.doi.org/10.1016/j.vaccine.2011.07.008
59. Appledorn DM, Aldhamen YA, Godbehere S, Seregin SS, Amalfitano A. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immuni. Clin Vaccine Immunol. 2011;18(1):150–60.
60. Patterson LJ, Kuate S, Daltabuit-Test M, Li Q, Xiao P, McKinnon K, et al. Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route. Clin Vaccine Immunol. 2012;19(5):629–37.
61. Choi JH, Schafer SC, Zhang L, Kobinger GP, Juelich T, Freiberg AN, et al. A single sublingual dose of an adenovirus-based vaccine protects against lethal ebola challenge in mice and guinea pigs. Mol Pharm. 2012;9(1):156–67.
62. Amuguni JH, Lee S, Kerstein KO, Brown DW, Belitsky BR, Herrmann JE, et al. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine [Internet]. 2011;29(29–30):4778–84. Available from: http://dx.doi.org/10.1016/j.vaccine.2011.04.083
63. Amuguni H, Lee S, Kerstein K, Brown D, Belitsky B, Herrmann J, et al. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. Microbes Infect [Internet]. 2012;14(5):447–56. Available from: http://dx.doi.org/10.1016/j.micinf.2011.12.001
64. Batista MT, Souza RD, Paccez JD, Luiz WB, Ferreira EL, Cavalcante RCM, et al. Gut adhesive Bacillus subtilis spores as a platform for mucosal delivery of antigens. Infect Immun. 2014;82(4):1414–23.
65. Murugappan S, Patil HP, Frijlink HW, Huckriede A, Hinrichs WLJ. Simplifying influenza vaccination during pandemics: Sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine. AAPS J. 2014;16(2):342–9.
66. Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A, et al. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. Vaccine [Internet]. 2014;32(20):2382–8. Available from: http://dx.doi.org/10.1016/j.vaccine.2013.12.043
67. Pedersen GK, Ebensen T, Gjeraker IH, Svindland S, Bredholt G, Guzmán CA, et al. Evaluation of the sublingual route for administration of influenza H5N1 virosomes in combination with the bacterial second messenger c-di-GMP. PLoS One. 2011;6(11).
68. Etchart N, Desmoulins P-O, Chemin K, Maliszewski C, Dubois B, Wild F, et al. Dendritic Cells Recruitment and In Vivo Priming of CD8 + CTL Induced by a Single Topical or Transepithelial Immunization Via the Buccal Mucosa with Measles Virus Nucleoprotein . J Immunol. 2001;167(1):384–91.
69. Buffa V, Klein K, Fischetti L, Shattock RJ. Evaluation of TLR Agonists as Potential Mucosal Adjuvants for HIV gp140 and Tetanus Toxoid in Mice. PLoS One. 2012;7(12):1–10.
70. Huang CF, Wu TC, Wu CC, Lee CC, Lo WT, Hwang KS, et al. Sublingual vaccination with sonicated Salmonella proteins and mucosal adjuvant induces mucosal and systemic immunity and protects mice from lethal enteritis. Apmis. 2011;119(7):468–78.
71. Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol. 2010;17(6):1005–12.